The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling

The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling

Obesity and nonalcoholic fatty liver disease (NAFLD) are global health concerns, and thus, drugs for the long-term treatment of these diseases are urgently needed. We previously discovered that the inositol pyrophosphate biosynthetic enzyme IP6K1 is a target in diet-induced obesity (DIO), insulin re...

Full description

Bibliographic Details
Main Authors: Sandip Mukherjee, Molee Chakraborty, Jake Haubner, Glen Ernst, Michael DePasquale, Danielle Carpenter, James C. Barrow, Anutosh Chakraborty
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Biomolecules
Subjects:
IP6K1
LI-2242
obesity
insulin resistance
NAFLD
Online Access:https://www.mdpi.com/2218-273X/13/5/868

Internet

https://www.mdpi.com/2218-273X/13/5/868

Similar Items